No content results match your keyword.
Content
You have successfully logged out.
Not registered yet?
No content results match your keyword.
Content
No product results match your keyword.
Products
Randomized controlled trials for ISR
First in Man Trials in Malaysia, Germany & Switzerland
Scheller B et al. Circ Cardiovasc Interv. 2022 Sep;15(9):e012305.
Design: Randomized | Prospective | Multicenter | Non-inferiority
Indication: DES-ISR
Control: SeQuent® Please NEO
Primary endpoints: LLL @ 6-month follow-up
Secondary endpoints:
101 patients (DES-ISR) | ||
51 patients | 50 patients | |
Follow-up: | ||
1 month | 6 months | 12 months |
Quantitative coronary angiography revealed no differences in baseline parameters.
After 6 months, in-segment late lumen loss was:
Mean difference between SCB and PCB was 0.01 (95% CI, -0.23 to 0.24).
Non-inferiority at a predefined margin of 0.35 was shown.
Angiographic patency: cumulative frequency distribution of in-segment late lumen loss determined by quantitative coronary angiography. Paclitaxel-coated balloon (PCB) versus sirolimus-coated balloon (SCB).
Clinical follow-up at 1 year
| SCB Total | PCB Total | P value SCB vs. PCB | |
| Number of patients (n [%]) | 50 (100) | 51 (100) | |
| TLR (n [%]) | 8 (16) | 5 (10) | 0.389 |
| Stent thrombosis (n [%]) | 0 | 1 (2) | 1.000 |
| Death (n [%]) | 1 (2) | 1 (2) | 1.000 |
| MI (n [%]) | 0 | 1 (2) | 1.000 |
| MACE (n [%]) | 9 (18) | 7 (14) | 0.596 |
Clinical events up to 12 months did not differ between the groups.
This first-in man comparison of a novel SCB with a crystalline coating showed similar angiographic and clinical outcomes in the treatment of coronary drug-eluting stent in-stent restenosis compared with PCB.
Your feedback matters! Participate in our customer survey to help us enhance our website, products and services. Thank you for your support!